Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Now in its 11th year, Springboard supports researchers at a critical point in their careers, when many are establishing laboratories for the first time and need the freedom to explore ambitious questions.

Pramila Rijal

Dr Pramila Rijal has been awarded £125,000 from the Academy's Springboard programme, in partnership with the Government's Department for Science, Innovation and Technology, Wellcome, and the British Heart Foundation.

This award comes at a pivotal stage in my career, enabling me to accelerate translational research to understand immune response and improve flu vaccines in order to protect more people from future outbreaks.  - Pramila Rijal

Springboard awards support researchers to take their first steps as independent group leaders, testing bold ideas with the potential to improve lives. For Pramila, the award will allow her to advance work on better and more broadly protective influenza vaccines.

Influenza remains a major global public health threat, causing substantial annual morbidity and mortality and carrying an ever-present risk of new pandemics.

More effective and broadly protective vaccines are essential both to mitigate seasonal epidemics and to strengthen pandemic preparedness. Pramila's work aims to develop broader-reactivity influenza vaccines that can better protect vulnerable populations and reduce the impact of future outbreaks.

The Academy of Medical Sciences has awarded £6.7 million to 55 early career researchers at 38 institutions across the UK. Read more on the Academy of Medical Sciences website.

Recent stories

Immune sensor can detect viral infection by monitoring cell’s own RNA

A recent study by the Rehwinkel Group and collaborators reveals a new way the immune sensor MDA5 can recognise viral infection – not only through viral RNA, but by monitoring changes to the cell’s own RNA processing.

New technology helps decode the genetic changes behind disease

Researchers from the Milne, Hughes and Davies Groups have developed a new technology that can reveal new therapeutic targets from common genetic variants linked to disease.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

MRC WIMM researchers win Health x AI Hackathon with tool to tackle delays in patient care

Three MRC WIMM researchers have won a £5,000 prize at a Health x AI Hackathon held at Google’s London headquarters, after developing an AI-powered tool designed to identify delays in patient care.

Expanding OxCITE: New funding to accelerate immunotherapy research

New funding from Cancer Research Horizons will help researchers to better understand why some patients respond well to immunotherapy while others do not.

Professor Marella de Bruijn receives MRC Programme Award

Congratulations to Professor de Bruijn, who has been awarded funding from the UKRI Medical Research Council to investigate how the first blood stem cells formed in the embryo acquire their exceptional regenerative potential, with the aim of informing future stem cell therapies.